Gene · 8317
NIH grants1,079
NIH grants whose papers are about the gene, through NIH's grant-paper links.
261 to 280 of 1,079
Download this page as JSON| Grant | Title | CDC7 papers | Newest fiscal year |
|---|---|---|---|
| R01CA222856 | An Integrative Approach to Identify Vulnerabilities in Pediatric Cancer DSRCT | 1 | 2024 |
| R01CA229535 | Novel role of APOBEC3 enzymes as key mediators of cisplatin sensitivity through aberrant processing of interstrand crosslinks | 1 | 2024 |
| R01CA236367 | DNA damage signaling to dormant origins of replication | 1 | 2024 |
| R01CA239164 | The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response | 1 | 2024 |
| R01CA239227 | FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers | 1 | 2024 |
| R01CA244341 | Characterization and targeting of rapid nucleotide exchange RAS mutations | 1 | 2024 |
| R01CA245318 | Antigen-independent prediction and biomarker identification of cancer-specific T cells | 1 | 2024 |
| R01CA245903 | Proteogenomics-driven therapeutic discovery in hepatocellular carcinoma | 1 | 2024 |
| R01CA248205 | Harnessing Aurora kinase inhibition‐induced cell death to enhance immunotherapy in HPV‐driven cancers | 1 | 2024 |
| R01CA254403 | Elucidating SAMHD1 in DNA Double-Strand Break Repair | 1 | 2024 |
| R01EB015611 | Solar-Eclipse Computational Tools for Imaging Genetics | 1 | 2024 |
| R01GM024129 | Transformylase Enzymes Dihydrofolate Reductase | 1 | 2024 |
| R01GM084192 | Structural and Functional Characterization of the Chd1 Chromatin Remodeler | 1 | 2024 |
| R01HD082568 | Identification and Functional Validation of Human Infertility Alleles | 1 | 2024 |
| R01HL105756 | CHARGE consortium: omics discovery for CVD and aging phenotypes | 1 | 2024 |
| R01HL108735 | Systems Biology Analyses for Hemodynamic Regulation of Vascular Homeostasis | 1 | 2024 |
| R15CA260126 | PA-23-189 for Kaya Johnson to CA260126-01: Identifying a proteomic signature for breast cancer detection in breast milk and serum | 1 | 2024 |
| R35GM136400 | Inter- and intracellular mechanisms of circadian regulation | 1 | 2024 |
| R35GM138109 | Elucidating the Mechanism in the Regulation of RNA-binding Protein Phase Separation | 1 | 2024 |
| R35GM138293 | Computational tools for estimating cell-type-specific effects in bulk RNA-seq and spatial transcriptomics data, using reference single-cell RNA-seq datasets | 1 | 2024 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8317/grants?page=14